Ewing's sarcoma Cancer from Detection to Treatment
What Is Ewing’s Sarcoma?
Ewing’s sarcoma is a malignant bone or soft-tissue tumor that usually affects children, teenagers, and young adults | ages 10-25.
It arises from primitive neuroectodermal cells and most commonly occurs in the pelvis | femur | tibia | ribs | or humerus.
Ewing’s sarcoma is a malignant bone or soft-tissue tumor that usually affects children, teenagers, and young adults | ages 10-25.
It arises from primitive neuroectodermal cells and most commonly occurs in the pelvis | femur | tibia | ribs | or humerus.
1. Initial Evaluation
Common Symptoms:
• Persistent bone pain, often worsening at night
• Swelling or tenderness over affected bone or soft tissue
• Warmth and redness resembling infection
• Limping or difficulty moving a limb
• In advanced cases ➧ fatigue | weight loss | or fever
Common Sites:
• Long bones ➧ femur | tibia | humerus
• Pelvis or ribs
• Spine or scapula
Common Symptoms:
• Persistent bone pain, often worsening at night
• Swelling or tenderness over affected bone or soft tissue
• Warmth and redness resembling infection
• Limping or difficulty moving a limb
• In advanced cases ➧ fatigue | weight loss | or fever
Common Sites:
• Long bones ➧ femur | tibia | humerus
• Pelvis or ribs
• Spine or scapula
2. Physical Examination
• Localized swelling | tenderness | or palpable mass
• Check for range of motion limitation if near a joint
• Evaluate for signs of systemic illness
If a painful swelling persists beyond 2 weeks, imaging is immediately ordered.
• Localized swelling | tenderness | or palpable mass
• Check for range of motion limitation if near a joint
• Evaluate for signs of systemic illness
If a painful swelling persists beyond 2 weeks, imaging is immediately ordered.
3. Imaging and Scanning Tests
X-ray
Shows classic “onion-skin” periosteal reaction or moth-eaten pattern.
Suggests malignant bone lesion ➧ leads to further scans.
Magnetic Resonance Imaging
Defines tumor size, extent, and invasion of soft tissues.
Vital for surgical and radiation planning.
CT Scan
Checks for lung metastases | most common site of spread.
Bone Scan | PET-CT
Detects metastases in other bones or distant sites.
X-ray
Shows classic “onion-skin” periosteal reaction or moth-eaten pattern.
Suggests malignant bone lesion ➧ leads to further scans.
Magnetic Resonance Imaging
Defines tumor size, extent, and invasion of soft tissues.
Vital for surgical and radiation planning.
CT Scan
Checks for lung metastases | most common site of spread.
Bone Scan | PET-CT
Detects metastases in other bones or distant sites.
4. Biopsy | Definitive Diagnosis
Types:
Core needle biopsy
Open surgical biopsy
Pathology Findings:
Small round blue cells under microscope.
Immunohistochemistry | CD99 positive, FLI-1 positive.
Genetic testing | FISH or RT-PCR
Confirms EWSR1-FLI1 gene fusion (t(11;22)(q24;q12)), diagnostic of Ewing’s sarcoma.
Types:
Core needle biopsy
Open surgical biopsy
Pathology Findings:
Small round blue cells under microscope.
Immunohistochemistry | CD99 positive, FLI-1 positive.
Genetic testing | FISH or RT-PCR
Confirms EWSR1-FLI1 gene fusion (t(11;22)(q24;q12)), diagnostic of Ewing’s sarcoma.
5. Staging | AJCC / Enneking System
I - Localized | low-grade
II - Localized | high-grade
III - Skip lesions in same bone
IV - Distant metastasis
I - Localized | low-grade
II - Localized | high-grade
III - Skip lesions in same bone
IV - Distant metastasis
6. Multidisciplinary Treatment Planning
Team includes:
• Pediatric or orthopedic oncologist
• Medical oncologist
• Radiation oncologist
• Radiologist
• Pathologist
• Rehabilitation specialist
• Psychologist/social worker
Team includes:
• Pediatric or orthopedic oncologist
• Medical oncologist
• Radiation oncologist
• Radiologist
• Pathologist
• Rehabilitation specialist
• Psychologist/social worker
7. Treatment Phases
➛ Neoadjuvant | Preoperative | Chemotherapy
Purpose:
Shrink the tumor
Kill micrometastatic cells
Improve surgical outcomes
Typical Regimen | VDC/IE:
V - Vincristine
D - Doxorubicin | Adriamycin
C - Cyclophosphamide
Alternating with
I - Ifosfamide
E - Etoposide
Cycle duration:
Every 2-3 weeks for 12-14 weeks before surgery/radiation.
➛ Local Control
After initial chemo, the tumor is re-evaluated with MRI.
Surgery:
Limb-sparing surgery is preferred whenever possible.
Amputation only if tumor involves critical neurovascular structures.
Margins checked for complete resection | R0.
Radiation Therapy:
Used when
• Surgery is not possible.
• Margins are positive after resection.
• As definitive therapy for unresectable tumors | pelvic, spine, rib.
Dose:
45-60 Gy over several weeks.
➛ Adjuvant | Postoperative | Chemotherapy
After local control, chemo continues for another 6-9 months using the same VDC/IE regimen.
Response is assessed by tumor necrosis percentage
➛ Neoadjuvant | Preoperative | Chemotherapy
Purpose:
Shrink the tumor
Kill micrometastatic cells
Improve surgical outcomes
Typical Regimen | VDC/IE:
V - Vincristine
D - Doxorubicin | Adriamycin
C - Cyclophosphamide
Alternating with
I - Ifosfamide
E - Etoposide
Cycle duration:
Every 2-3 weeks for 12-14 weeks before surgery/radiation.
➛ Local Control
After initial chemo, the tumor is re-evaluated with MRI.
Surgery:
Limb-sparing surgery is preferred whenever possible.
Amputation only if tumor involves critical neurovascular structures.
Margins checked for complete resection | R0.
Radiation Therapy:
Used when
• Surgery is not possible.
• Margins are positive after resection.
• As definitive therapy for unresectable tumors | pelvic, spine, rib.
Dose:
45-60 Gy over several weeks.
➛ Adjuvant | Postoperative | Chemotherapy
After local control, chemo continues for another 6-9 months using the same VDC/IE regimen.
Response is assessed by tumor necrosis percentage
8. Treatment of Metastatic or Recurrent Disease
Metastatic ➧ systemic chemo + surgical removal of lung nodules if possible.
Recurrent ➧ high-dose chemotherapy, radiation, or stem cell transplant in select cases.
Targeted/Immunotherapy | research stage:
• IGF-1R inhibitors
• PARP inhibitors
• Immunotherapies
Metastatic ➧ systemic chemo + surgical removal of lung nodules if possible.
Recurrent ➧ high-dose chemotherapy, radiation, or stem cell transplant in select cases.
Targeted/Immunotherapy | research stage:
• IGF-1R inhibitors
• PARP inhibitors
• Immunotherapies
9. Supportive and Rehabilitation Care
➛ Pain management and antiemetics during chemo.
➛ Blood transfusions or growth factors for low counts.
➛ Physical therapy after surgery for mobility restoration.
➛ Prosthetic fitting and rehabilitation | if amputation.
➛ Psychological counseling for patient and family.
➛ Nutritional support to maintain strength during treatment.
➛ Pain management and antiemetics during chemo.
➛ Blood transfusions or growth factors for low counts.
➛ Physical therapy after surgery for mobility restoration.
➛ Prosthetic fitting and rehabilitation | if amputation.
➛ Psychological counseling for patient and family.
➛ Nutritional support to maintain strength during treatment.
10. Follow-up and Monitoring
After Treatment:
Every 3 months for first 2 years
Every 6 months for next 3 years
Annually after 5 years
Includes:
Physical exam
MRI of original site
Chest CT for metastasis
Bone scan if symptoms suggest recurrence
After Treatment:
Every 3 months for first 2 years
Every 6 months for next 3 years
Annually after 5 years
Includes:
Physical exam
MRI of original site
Chest CT for metastasis
Bone scan if symptoms suggest recurrence
Read More
➛ Step by Step Overview
➛ Patient's Appeal
➛ Patients’ Stories
➛ Transparency Page
➛ Volunteer / Partner Page